UPMBiomedicals

UPM joins the new consortium to investigate theranostic potential of extracellular vesicles

Press Release 16.2.2020 11:00 EET

(UPM, Helsinki, 17 February 2020 at 11:00 EET) 

UPM has joined a newly formed Finnish research consortium that plans to use extracellular vesicles to develop novel nano-biotechnological solutions for the early diagnostics and treatment of severe progressive diseases. The Extracellular Vesicles Ecosystem for Theranostic Platforms (EVE) project brings UPM together with many of Finland’s leading research organisations, the Finnish Red Cross Blood Service, Orion Pharma and a number of SMEs, and aims to establish whether extracellular vesicles can be used in the treatment and diagnostics of cancers and degenerative diseases of the central nervous system.

The three year project, which is being funded by Business Finland and a total of 13 consortium partners, is being led by the Finnish Red Cross Blood Service’s R&D Manager, Saara Laitinen: “We are now going to find out whether extracellular vesicles produced by blood cells have special characteristics that could be used therapeutically in severe diseases. If extracellular vesicles served as vehicles of drug delivery, we would be able to make even more versatile use of donated blood in the treatment of patients,” said Saara.

One of the key objectives of the EVE project is to develop the technical, production and quality control capabilities required by researchers to develop medicinal products from blood cells. “We are very excited to be part of this ambitious project to advance extracellular vesicle technologies,” said Dr Jane Spencer-Fry, Director, UPM Biomedicals. “Our natural, biocompatible hydrogels are free from animal-derived components, making them ideally suited to this type of biomedical research.”

 

For more information on EVE, please contact:

Saara Laitinen, R&D Manager, Finnish Red Cross Blood Service, tel. +358 29 300 1695 saara.laitinen(at)veripalvelu.fi

 For further information on UPM, please contact:

Jane Spencer-Fry, Director, UPM Biomedicals, tel. +44 7881 557511

Kari Luukko, Director, Quality management and regulatory affairs, UPM Biomedicals, tel. +358 400 259 866

 

UPM, Media Relations

Mon-Fri 9:00-16:00 EET

tel. +358 40 588 3284

media@upm.com

UPM

We deliver renewable and responsible solutions and innovate for a future beyond fossils across six business areas: UPM Biorefining, UPM Energy, UPM Raflatac, UPM Specialty Papers, UPM Communication Papers and UPM Plywood. We employ around 19,000 people worldwide and our annual sales are approximately EUR 10.5 billion. Our shares are listed on Nasdaq Helsinki Ltd. UPM Biofore – Beyond fossils. www.upm.com